|
|||||
|
|
Potential unrealized mortality benefit of glucagon-like peptide-1 receptor agonists and sodium-glucose co-transport-2 inhibitors: A report from the Veterans Health Administration Clinical Assessment,Reporting and Tracking program |
|
| Authors: | Taufiq Salahuddin MD Vanessa Richardson BA Demetria M. McNeal PhD Kamal Henderson MD Paul L. Hess MD Sridharan Raghavan MD David R. Saxon MD Javier A. Valle MD Stephen W. Waldo MD P. Michael Ho MD Gregory G. Schwartz MD |
| Affiliation: | 1. Cardiology Section, Rocky Mountain Regional VA Medical Center, Aurora, Colorado, USA;2. University of Colorado School of Public Health, Aurora, Colorado, USA;3. University of Colorado School of Medicine, Aurora, Colorado, USA;4. Cardiology Section, Rocky Mountain Regional VA Medical Center, Aurora, Colorado, USA University of Colorado School of Medicine, Aurora, Colorado, USA;5. University of Colorado School of Medicine, Aurora, Colorado, USA Section of Hospital Medicine, Rocky Mountain Regional VA Medical Center, Aurora, Colorado, USA;6. University of Colorado School of Medicine, Aurora, Colorado, USA Endocrinology Section, Rocky Mountain Regional VA Medical Center, Aurora, Colorado, USA;7. Cardiology Section, Rocky Mountain Regional VA Medical Center, Aurora, Colorado, USA University of Colorado School of Medicine, Aurora, Colorado, USA Denver-Seattle Center of Innovation for Veteran Centered and Value Driven Care, Denver, Colorado, USA |
| Abstract: | |
| Keywords: | cardiovascular disease empagliflozin GLP-1 liraglutide SGLT2 inhibitor type 2 diabetes |